Twenty-one cases of the ‘Delta plus’ variant of Covid-19, considered highly infectious, have been reported in Maharashtra threatening to massively dent the state’s fight against the virus as experts warn that this variant may trigger a third wave of the pandemic in the state.
Kerala, Karnataka, and Madhya Pradesh, too, have reported cases of this deadlier variety. And even though, only about 200 confirmed infections have been detected across the globe, of which 30 are in India, fears remain that the virus mutant may wreak havoc in the near future.
Everything we know:
- The new Delta plus variant has been formed due to a mutation in the Delta or B.1.617.2 variant, first identified in India and one of the drivers of the deadly second wave.
- It has been detected in nine countries, inclduing UK, Portugal, Switzerland, Poland, Japan, Nepal, China, and Russia, apart from India.
- In Maharashtra, the highest nine cases were reported in Ratnagiri, followed by seven in Jalgaon, two in Mumbai, and one case each in Palghar, Thane and Sindhudurg districts.
- In Kerala, at least three cases have been found in samples collected from Palakkad and Pathanamthitta. One of them is a four-year-old boy from Kadapra panchayat.
- A 65-year-old woman From Madhya Pradesh Capital Bhopal has tested positive for the new Delta Plus variant of coronavirus. The woman, who has taken two shots of Covid-19 vaccine, had recovered in home isolation. “So far five cases of the Delta Plus variant have been reported in Madhya Pradesh. Four out of five people who got the vaccine are healthy. One has died,” said Madhya Pradesh Health Minister Prabhuram Choudhary.
- Karnataka Health Minister K Sudhakar said on Tuesday that two cases of the Delta Plus variant have been detected in the state.
- The Delta plus variant is not yet a variant of concern’, the Union health ministry said on June 16, due to relatively low incidence.
- The earliest sequence of this genome was found in Europe in late March this year.
What is Delta Plus?
As India was hit by the second wave of Covid-19 hit earlier this year, experts partly blamed it on a triple mutant of the novel coronavirus of B.1.617.2 lineage, detected in India at the end of last year. The World Health Organization (WTO) named it Delta on May 31. Later, the highly transmissible variant of Sars-CoV-2 mutated further into Delta Plus of AY.1 lineage. Scientists added that there is no immediate cause for concern as its incidence in the country is still low.
The new strain Delta Plus contains a K417N mutation in its spike protein, which has been formally designated B.1.617.2.1. According to media reports, the first sequence of this type was discovered in Europe in March 2021.
The National Chemical Laboratory (CSIR-NCL) is now studying the Ratnagiri and Sindhudurg specimens from Maharashtra to determine the presence of the Delta Plus variation. These two regions specifically have the highest proportion of active infections in India.
The newest variant is still being studied and scientists are trying to pinpoint key differences between symptoms caused by Covid-19 and the Delta plus mutant. Preliminary studies seem to suggest that apart from the usual dry cough, fever, tiredness, aches and pains, skin rashes, toes and fingers discoloration, sore throat, conjunctivitis, loss of taste and smell loss, diarrhea, and headache, chest pain, breathlessness, shortness of breath, and speech loss, Delta plus patients also exhibited stomach ache, nausea, appetite loss, vomiting, joint pains, hearing impairment, etc.
Resistant to monoclonal antibodies?
Experts are currently attempting to figure out how this novel variation affects illness development and if it causes severe Covid-19 infection. However, preliminary findings suggest that this novel variation may be resistant to monoclonal antibody cocktail treatments for COVID-19. The therapy, which was recently approved in India, consists of a combination of two drugs: casirivimab and imdevimab.
Another potential concern that is still being researched by medical experts is that the new variant may be able to bypass the immunity provided by both vaccines and prior Covid-19 infections.
Do vaccines work?
Scientists are yet to test the effectiveness of vaccines on the Delta Plus variant but Dr Scott Gottlieb, the former commissioner of the Food and Drug Administration (FDA) was quoted as cnbc.com as saying that vaccines do seem to be effective.
“The mRNA vaccine seems to be highly effective, about 88 percent against the Delta variant. The viral vector vaccines from Johnson & Johnson and AstraZeneca also appear to be about 60 percent effective,” he said. The vaccines developed by Moderna and Pfizer/BioNTech use mRNA technology.
According to research, the Pfizer and AstraZeneca vaccines were found to be only 33 percent effective three weeks after the first dose against symptomatic cases of the Delta variant, compared to 50 percent effective for the Alpha variant.
Bharat Biotech also said that Covaxin “demonstrates protective response” against the Delta and Beta variants. A study by the National Institute of Virology in Pune, the Indian Council of Medical Research, and Bharat Biotech has confirmed this.
However, a study by AIIMS the All India Institute of Medical Sciences on a small group of 63 people suggested that neither Covishield nor Covaxin were effective against the variant.
Threat to Maharashtra
The Delta plus variant could stoke the third wave in Maharashtra, according to a presentation made by the state health department at a meeting attended by Chief Minister Uddhav Thackeray last week. The number of active patients could reach up to eight lakh, while 10 per cent out of them could be children, the state government was warned.
“It could spread at double the rate,” said an official during the presentation. Chief Minister Uddhav Thackeray has asked officials to be prepared to deal with any situation in terms of the availability of medicines, beds and other necessary resources.
Should India worry?
Health experts have warned that the Delta Plus or AY.01 variant may unleash a third wave in the coming months, as it could possibly circumvent the body’s immune system.
The prevalence of this new variant is still low in India, data shows., but Delta still remains the dominant variant in the country as of now.
However, there is no certainty and the current low number is no indication of any trend. As trends go, the Delta variant too had been detected in extremely low numbers at the beginning of the second surge in India that claimed countless lives and reaching epic transmissibility levels in a short span of two and a half months. Dr VK Paul, member (Health), NITI Aayog, points out that the right way forward is to watch for its spread in the country and make an appropriate public health response, in which vaccines play a crucial role.